Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/nanopublications.trig#NP165670.RAq6gwjBndk_g8Efc4SF946wK_46sFGpaUMZA-XX1wDso130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP165670.RAq6gwjBndk_g8Efc4SF946wK_46sFGpaUMZA-XX1wDso130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP165670.RAq6gwjBndk_g8Efc4SF946wK_46sFGpaUMZA-XX1wDso130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP165670.RAq6gwjBndk_g8Efc4SF946wK_46sFGpaUMZA-XX1wDso130_provenance.
- NP165670.RAq6gwjBndk_g8Efc4SF946wK_46sFGpaUMZA-XX1wDso130_assertion wasGeneratedBy ECO_0000203 NP165670.RAq6gwjBndk_g8Efc4SF946wK_46sFGpaUMZA-XX1wDso130_provenance.
- NP165670.RAq6gwjBndk_g8Efc4SF946wK_46sFGpaUMZA-XX1wDso130_assertion wasDerivedFrom befree-20140225 NP165670.RAq6gwjBndk_g8Efc4SF946wK_46sFGpaUMZA-XX1wDso130_provenance.
- NP165670.RAq6gwjBndk_g8Efc4SF946wK_46sFGpaUMZA-XX1wDso130_assertion SIO_000772 22271575 NP165670.RAq6gwjBndk_g8Efc4SF946wK_46sFGpaUMZA-XX1wDso130_provenance.
- NP165670.RAq6gwjBndk_g8Efc4SF946wK_46sFGpaUMZA-XX1wDso130_assertion evidence source_evidence_literature NP165670.RAq6gwjBndk_g8Efc4SF946wK_46sFGpaUMZA-XX1wDso130_provenance.
- NP165670.RAq6gwjBndk_g8Efc4SF946wK_46sFGpaUMZA-XX1wDso130_assertion description "[Enzymatic inhibitors of Janus kinase 2 (JAK2) are in clinical development for the treatment of myeloproliferative neoplasms (MPNs), B cell acute lymphoblastic leukemia (B-ALL) with rearrangements of the cytokine receptor subunit cytokine receptor-like factor 2 (CRLF2), and other tumors with constitutive JAK2 signaling.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP165670.RAq6gwjBndk_g8Efc4SF946wK_46sFGpaUMZA-XX1wDso130_provenance.
- befree-20140225 importedOn "2014-02-25" NP165670.RAq6gwjBndk_g8Efc4SF946wK_46sFGpaUMZA-XX1wDso130_provenance.